A Phase 3 interventional study of BMS-188667 and Mycophenolate mofetil in Lupus Nephritis, sponsored by Bristol-Myers Squibb. Terminated at 149 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-26.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.
Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 2nd largest by enrollment of the 100 interventional ones that give a count, is one of 6 that started in 2013, is one of 16 in phase 3, and was the 22nd registered.
343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.
Browse Lupus Nephritis studies →39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
iCell Gene Therapeutics · Sites in United States
Ages 16–70
Akebia Therapeutics · Sites in United States, Brazil
Ages 16+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 47 · Phase 3 17 · Phase 4 7
First in 1994; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 695 is above the median of 48 across 242 interventional studies indexed under Lupus Nephritis.
Median enrollment 50 across the 100 interventional studies, 265 across the 14 observational. Of the 53 that completed or were terminated, 31 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 114 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 6 studies filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
11 of the studies in Lupus Nephritis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT06518668Hospital for Special Surgery, New YorkA Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus | 2026-12 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT06217107Morehouse School of MedicineWellness & Workforce Solution for Lupus/Lupus Nephritis | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 114 studies in Lupus Nephritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate (Abatacept) for treatment of lupus nephritis when used on a background of Cellcept (mycophenolate) and prednisone (corticosteroids)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For additional information please contact the BMS Lupus Nephritis Clinical Trial Matching Service at 855-56-LUPUS. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.
Note: Subjects > 16 are eligible for enrollment at selected centers
Inclusion Criteria:
There must also be evidence of active disease within 3 months of Screening, based on at least one of the following:
Inclusion Criteria for the Long-Term Extension Period:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMS-188667 30 mg/kg injection by intravenous on Days 1,15, 29, and 57, followed by a weight-tiered dose approximating 10mg/kg injection by intravenous every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 weeks
Biological: BMS-188667 · Drug: Mycophenolate mofetil · Drug: Prednisone
Placebo matching with BMS-188667 injection by intravenous on Days 1,15, 29, and 57, followed by every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 Weeks
Drug: Mycophenolate mofetil · Drug: Prednisone · Biological: Placebo matching with BMS-188667
Also known as: Abatacept
Also known as: Cellcept
Percentage of Participants in Complete Renal Response (CR) of Lupus Glomerulonephritis at Day 365 of the Double-blind Period
Number of participants achieving CR was divided by the total number of participants in that arm and expressed as a percentage. CR defined as: eGFR is normal or no \<85% of the baseline; eGFR based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equiv. for at least 28 days prior to assessment. Participants with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as having achieved CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use (Yes/No), race (Asian/ Black/Caucasian/Other) and baseline UPCR as a continuous variable.
Time frame: Day 365
Percentage of Nephrotic Participants in Complete Renal Response of Lupus Glomerulonephritis at Day 365 of the Double-blind Period
Number of participants achieving CR was divided by total participants in that arm, expressed as a percentage. CR is defined the following criteria: eGFR is normal or no \<85% of the baseline value; eGFR is based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equivalent for at least 28 days prior. Subjects with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use, race and baseline UPCR as a continuous variable.
Time frame: Day 365
Adjusted Mean Change From Baseline in Urine Protein/Creatinine Ratio (UPCR) at Day 365 of the Double-blind Period in Nephrotic Participants
Adjusted Mean Change from Baseline in UPCR at Day 365 of the double-blind period in nephrotic participants
Time frame: Baseline and Day 365
Adjusted Mean Change From Baseline in UPCR at Day 365 of the Double-blind Period in Overall Population
Adjusted Mean Change from Baseline in Urine protein/creatinine ratio (UPCR) at Day 365 of the double-blind period in the overall population
Time frame: Day 1 and Day 365
Adjusted Mean Change From Baseline in Disease Activity as Measured by BILAG 2004 Over Time During Year 1 of the Double-blind Period
Adjusted mean change from baseline in British Isles Lupus Assessment Group (BILAG) score over time during Year 1 of the double-blind period based on a repeated measure mixed model and presented at each visit in the first 12-month of the double-blind period. BILAG index measures disease activity in different organs/systems separately. BILAG score is calculated for each of 9 systems depending on the clinical features present and whether they are new (4 points), worse (3 points), the same (2 points), improving (1 point) or not present (0 points) in the last 4 weeks compared with previously. BILAG "A" represents the presence of serious features of lupus. BILAG "B" represents more moderate features of the disease. BILAG "C" includes only mild symptomatic features. BILAG "D" represents prior activity with no current symptoms due to active lupus. BILAG "E" represents an organ that has never been involved. Overall BILAG score ranges from 0-108, with higher scores reflecting a worse outcome.
Time frame: Day 1 to Day 365
Number of Participants With Any Adverse Events (AEs) During Year 1 of the Double-blind Period
All AEs were coded and grouped into preferred terms (PT) by system organ class (SOC), using the Medical Dictionary for Regulatory Activities (MedDRA, version 21.0). Investigators determined the intensity of each AE as mild, moderate, severe, or very severe and assessed the relationship to study drug.
Time frame: From Day 1 up to 56 days post last dose in Year 1 of the double-blind period
Percentage of Participants With Ranked Outcome of Complete Renal Response, Partial Renal Response (PR), and No Renal Response (NR) During the Double-blind Period
Complete Renal Response or Complete Response (CR): defined as meeting ALL of the following criteria: eGFR normal OR no less than 85% of the baseline value; UPCR \< 0.5; Urine sediment: No cellular casts; Daily corticosteroid dose must be no greater than 10 mg prednisone or equivalent for at least 28 days prior to assessment. Partial Renal Response or Partial Response (PR): defined as meeting ALL of the following criteria: Participant does not meet criteria for CR; eGFR no less than 85% of the lesser of the values at screening or randomization (Day 1); UPCR \< 0.5 OR 50% reduced from baseline and \< 1 if baseline value was \< 3, OR 50% reduced from baseline and \< 3 if baseline value was greater than or equal to 3; Urine sediment: no cellular casts; daily corticosteroid dose no greater than 10 mg/day prednisone or prednisone equivalent for at least 28 days prior to assessment. No Renal Response or No Response (NR): defined as not meeting criteria for CR or PR or withdrawn
Time frame: Day 365, Day 729
Median Time to Complete Renal Response During the Double-blind Period in All Participants
The estimate of median time to Complete Renal Response is based on Kaplan-Meier analysis. Complete renal response (CR): defined as meeting ALL of the following criteria: eGFR normal OR no less than 85% of the baseline value; Urine protein/creatinine ratio (UPCR) \< 0.5; Urine sediment: No cellular casts; Daily corticosteroid dose must be no greater than 10 mg prednisone or equivalent for at least 28 days prior to assessment.
Time frame: Day 365, Day 729
Median Time to Complete Renal Response During the Double-blind Period in Nephrotic Participants
The estimate of median time to Complete Renal Response in nephrotic participants is based on Kaplan-Meier analysis. Complete renal response (CR): defined as meeting ALL of the following criteria: eGFR normal OR no less than 85% of the baseline value; Urine protein/creatinine ratio (UPCR) \< 0.5; Urine sediment: No cellular casts; Daily corticosteroid dose must be no greater than 10 mg prednisone or equivalent for at least 28 days prior to assessment.
Time frame: Day 365, Day 729
Median Time to Partial Renal Response During the Double-blind Period in All Participants
The estimate of median time to Partial Response (PR) is based on Kaplan-Meier analysis. Partial renal response (PR): defined as meeting ALL of the following criteria: Participant does not meet criteria for CR; eGFR no less than 85% of the lesser of the values at screening or randomization (Day 1); UPCR \< 0.5 OR 50% reduced from baseline and \< 1 if baseline value was \< 3, OR 50% reduced from baseline and \< 3 if baseline value was 3; Urine sediment: no cellular casts; daily corticosteroid dose no greater than 10 mg/day prednisone or prednisone equivalent for at least 28 days prior to assessment
Time frame: Day 365, Day 729
Median Time to Partial Renal Response During the Double-blind Period in Nephrotic Participants
The estimate of median time to Partial Response (PR) in nephrotic participants is based on Kaplan-Meier analysis. Partial renal response (PR): defined as meeting ALL of the following criteria: Participant does not meet criteria for CR; eGFR no less than 85% of the lesser of the values at screening or randomization (Day 1); UPCR \< 0.5 OR 50% reduced from baseline and \< 1 if baseline value was \< 3, OR 50% reduced from baseline and \< 3 if baseline value was 3; Urine sediment: no cellular casts; daily corticosteroid dose no greater than 10 mg/day prednisone or prednisone equivalent for at least 28 days prior to assessment
Time frame: Day 365, Day 729
Adjusted Mean Change From Baseline in UPCR Over Time
A repeated measure mixed model that included the baseline UPCR value, randomization stratification factors, time, and time by treatment interaction as fixed effects and subject as a random effect was used.
Time frame: Day 365; Day 729, includes data up to July 1st 2017 when double-blind therapy ended
Median Percent Change From Baseline in UPCR Over Time
A repeated measure mixed model that included the baseline UPCR value, randomization stratification factors, time, and time by treatment interaction as fixed effects and subject as a random effect was used. % Change from Baseline = (post baseline - baseline value) / baseline value x 100
Time frame: Day 365, Day 729
Adjusted Mean Change From Baseline in eGFR Over Time
Estimated glomerular filtration rate(eGFR), will be calculated by the CKD-EPI formula shown below.50 eGFR is expressed as mL/min per 1.73m2. For the purpose of this study lower limit of normal eGFR is defined as 90mL/min per 1.73m2 eGFR = 141 X min (Scr/k, 1)α X max (Scr/k, 1)-1.209 X 0.993Age X (1.018 \[if female\]) X (1.159 \[if black\]) Where Scr is serum creatinine (mg/dL), k is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/k or 1, and max indicates the maximum of Scr/k or 1, age in years.
Time frame: Day 365, Day 729
Median Time to First Sustained Change to No Response During the Double-blind Period
Sustained response defined as response present at 2 consecutive visits approximately 4 weeks apart. No renal response (NR): defined as not meeting criteria for CR or PR or withdrawn The estimate of median time is based on Kaplan-Meier analysis
Time frame: Day 365, Day 729
Number of Participants With Sustained Change From Higher Level of Response to no Response During the Double-blind Period
Sustained change to no response is defined as going from CR (or PR) to NR and remaining in NR for at least 2 consecutive visits; visits should be approximately 4 weeks apart. This analysis will be based on time from response CR (or PR) to the first visit in which the no response (NR) was achieved and sustained to the next visit.
Time frame: Day 365, Day 729
Adjusted Mean Change From Baseline in Disease Activity as Measured by BILAG 2004 Over Time During the Double-blind Period
BILAG index measures and reports disease activity in different organs/systems separately. The BILAG score is calculated for each of nine systems depending on the clinical features present and whether they are new (4 points), worse (3 points), the same (2 points), improving (1 point) or not present (0 points) in the last 4 weeks compared with previously. A BILAG "A" represents the presence of one or more serious features of lupus. A BILAG "B" represents more moderate features of the disease. A BILAG "C" includes only mild symptomatic features. A BILAG "D" represents only prior activity with no current symptoms due to active lupus. A BILAG "E" represents an organ that has never been involved. Overall BILAG score ranges from 0-108, with higher scores reflecting a worse outcome.
Time frame: Day 1 to Day 729; Day 365 to Day 729
Cmin (ug/mL): Trough Level Serum Concentration of Abatacept Prior to the Administration of the IV Infusion
Trough level serum concentration of abatacept prior to the administration of the IV infusion on Days 1 to 365
Time frame: Days 1 to 365
Cmax: Maximum Observed Serum Concentration Following Participants Receiving Active Abatacept IV
Cmax: Maximum observed serum concentration following participants receiving active abatacept IV
Time frame: at 1 hour post Day 1 dose and 30 minutes post Day 337 dose
AUC (TAU): Area Under the Serum Concentration Time Curve Over a Dosing Interval
AUC (TAU): Area under the serum concentration time curve over a dosing interval between Days 337 to 365.
Time frame: Days 337 to 365
Summary Statistics for Systolic Blood Pressure
Summary statistics for systolic blood pressure
Time frame: Day 1 to Day 729
Summary Statistics for Diastolic Blood Pressure
Summary statistics for diastolic blood pressure
Time frame: Day 1 to Day 729
Summary Statistics for Heart Rate
Summary statistics for Heart Rate
Time frame: Day 1 to Day 729
Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (U/L)
Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.
Time frame: Day 729
Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (g/L)
Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.
Time frame: Day 729
Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (Percentage of Blood)
Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.
Time frame: Day 729
Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (Umol/L)
Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.
Time frame: Day 729
Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (mmol/L)
Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.
Time frame: Day 729
Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (x10^9 Cells/L)
Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.
Time frame: Day 729
Number of Participants With Marked Hematology Laboratory Abnormalities During Year 1 of the Double Blind Period
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value HEMOGLOBIN g/L 4.0 HB \>3 G/DL DECREASE FROM PRE RX HEMATOCRIT vol 6.3 HCT \<0.75X PRE RX ERYTHROCYTES x10\*12 c/L 5.2 RBC \<0.75X PRE RX PLATELET COUNT x10\*9 c/L 5.0 PLAT \<0.67X LLN OR \>1.5X ULN, OR IF PRE RX\<LLN THEN USE 0.5X PRE RX AND \<100,000/MM3 LEUKOCYTES x10\*9 c/L 6.2 WBC \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.8X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.2X PRE RX OR \<LLN EOSINOPHILS (ABSOLUTE) x10\*9 c/L 8.3 EOSA IF VALUE \> .750 X10\*3 c/uL BASOPHILS (ABSOLUTE) x10\*9 c/L 8.3 BASOA IF VALUE \> 400/MM3 MONOCYTES (ABSOLUTE) x10\*9 c/L 8.3 MONOA IF VALUE \> 2000/MM3 LYMPHOCYTES (ABSOLUTE) x10\*9 c/L 8.3 LYMPA IF VALUE \< .750 X10\*3 c/uL OR IF VALUE \> 7.50 X10\*3 c/uL N = the number of participants with at least 1 on treatment lab result for each analyte
Time frame: Day 1 to Day 365; includes data up to 56 days post last dose in year 1 of double-blind period or first dose date in the year 2 of double-blind period, whichever is earlier
Number of Participants With Marked Liver and Kidney Function Laboratory Abnormalities During Year 1 of the Double Blind Period
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value ALKALINE PHOSPHATASE (ALP) U/L 5.0 ALP \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX ASPARTATE AMINOTRANSFERASE (AST) U/L 5.0 AST \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX ALANINE AMINOTRANSFERASE (ALT) U/L 5.0 ALT \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX G-GLUTAMYL TRANSFERASE (GGT) U/L 5.0 GGT \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX BILIRUBIN, TOTAL umol/L 5.1 TBILI \>2X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX BILIRUBIN, DIRECT umol/L 5.1 DBILI \>1.5X ULN, OR IF PRE RX\>ULN THEN USE \>2X PRE RX BLOOD UREA NITROGEN mmol/L 5.1 BUN \>2X PRE RX CREATININE umol/L 5.0 CREAT \>1.5X PRE RX N = the number of participants with at least 1 on treatment lab result for each analyte
Time frame: Day 1 to Day 365; includes data up to 56 days post last dose in year 1 of double-blind period or first dose date in the year 2 of double-blind period, whichever is earlier
Number of Participants With Marked Electrolyte Laboratory Abnormalities During Year 1 of the Double Blind Period
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value SODIUM, SERUM mmol/L 4.0 NA \<0.95X LLN OR \>1.05X ULN, OR IF PRE RX\<LLN THEN USE \<0.95X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.05X PRE RX OR \<LLN POTASSIUM, SERUM mmol/L 4.1 K \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN CHLORIDE, SERUM mmol/L 5.0 CL \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN N = the number of participants with at least 1 on treatment lab result for each analyte
Time frame: Day 1 to Day 365; includes data up to 56 days post last dose in year 1 of double-blind period or first dose date in the year 2 of double-blind period, whichever is earlier
Number of Participants With Marked Urinalysis Laboratory Abnormalities During Year 1 of the Double Blind Period
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value PROTEIN, URINE Unknown UPRO IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 GLUCOSE, URINE N/A UGLU IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 BLOOD, URINE N/A UBLD IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 RBC, URINE hpf 5.0 URBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 WBC, URINE hpf 5.0 UWBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4
Time frame: Day 1 to Day 365; includes data up to 56 days post last dose in year 1 of double-blind period or first dose date in the year 2 of double-blind period, whichever is earlier
Number of Participants With Other Marked Chemistry Laboratory Abnormalities During Year 1 of the Double Blind Period
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value CALCIUM, TOTAL mmol/L 5.2 CA \<0.8X LLN OR \>1.2X ULN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.25X PRE RX OR \<LLN PHOSPHORUS, INORGANIC mmol/L 5.2 PHOS \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.67X PRE RX OR \>ULN GLUCOSE, SERUM mmol/L 4.1 GLUC \<65 mg/dL, OR \>220 mg/dL PROTEIN, TOTAL g/L 5.0 TPRO \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE 0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE 1.1X PRE RX OR \<LLN ALBUMIN g/L 3.0 ALB \<0.9X LLN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX CHOLESTEROL, TOTAL (TC) mmol/L 5.2 CHOL \>2X PRE R N = the number of participants with at least 1 on treatment lab result for each analyte
Time frame: Day 1 to Day 365; includes data up to 56 days post last dose in year 1 of double-blind period or first dose date in the year 2 of double-blind period, whichever is earlier
Number of Participants With Any Adverse Events (AEs) During Year 2 of the Double-blind Period and Long-term Extension
All AEs were coded and grouped into preferred terms (PT) by system organ class (SOC), using the Medical Dictionary for Regulatory Activities (MedDRA, version 21.0). Investigators determined the intensity of each AE as mild, moderate, severe, or very severe and assessed the relationship to study drug.
Time frame: From the first dose in Year 2 of the double-blind period up to 56 days post last dose
Percentage of Participants in Treatment Failure Over Time During the Double-blind Period
Lupus treatment failure is defined as any of the following: Death, unless due to physical trauma or violence; Renal Flare; sustained doubling of creatinine from baseline (greater of Screening or Study Day 1 value); initiation of rescue therapy for treatment of active lupus nephritis after Study Week 20. Overall treatment failure is defined as lupus treatment failure plus discontinuation of study drug for any reason except death due to physical trauma or violence, pregnancy or administrative decision by Sponsor.
Time frame: Day 365, Day 729
Median Time to First Treatment Failure and Overall Treatment Failure During the Double-blind Period
First treatment failure (or Lupus treatment failure) is defined as any of the following: Death, unless due to physical trauma or violence; Renal Flare; sustained doubling of creatinine from baseline (greater of Screening or Study Day 1 value); initiation of rescue therapy for treatment of active lupus nephritis after Study Week 20. Overall treatment failure is defined as lupus treatment failure plus discontinuation of study drug for any reason except death due to physical trauma or violence, pregnancy or administrative decision by Sponsor. The hazard ratio is estimated using the Cox proportional hazards model which includes treatment group, stratification variables (baseline ACEis/ARBs use, RACE) and baseline UPCR. The estimate of median time is based on Kaplan-Meier analysis
Time frame: Day 365, Day 729
Percentage of Nephrotic Participants in Complete Renal Response of Lupus Glomerulonephritis at Day 729 of the Double-blind Period
Number of participants achieving CR was divided by total participants in that arm, expressed as a percentage. CR is defined the following criteria: eGFR is normal or no \<85% of the baseline value; eGFR is based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equivalent for at least 28 days prior. Subjects with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use, race and baseline UPCR as a continuous variable.
Time frame: Day 729
Percentage of Participants in Overall Population in Complete Renal Response of Lupus Glomerulonephritis at Day 729 of the Double-blind Period
Number of participants achieving CR was divided by total participants in that arm, expressed as a percentage. CR is defined the following criteria: eGFR is normal or no \<85% of the baseline value; eGFR is based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equivalent for at least 28 days prior. Subjects with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use, race and baseline UPCR as a continuous variable.
Time frame: Day 729
Number of Participants With Marked Hematology Laboratory Abnormalities in the Double Blind Period
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value HEMOGLOBIN g/L 4.0 HB \>3 G/DL DECREASE FROM PRE RX HEMATOCRIT vol 6.3 HCT \<0.75X PRE RX ERYTHROCYTES x10\*12 c/L 5.2 RBC \<0.75X PRE RX PLATELET COUNT x10\*9 c/L 5.0 PLAT \<0.67X LLN OR \>1.5X ULN, OR IF PRE RX\<LLN THEN USE 0.5X PRE RX AND \<100,000/MM3 LEUKOCYTES x10\*9 c/L 6.2 WBC \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.8X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.2X PRE RX OR \<LLN EOSINOPHILS (ABSOLUTE) x10\*9 c/L 8.3 EOSA IF VALUE \> .750 X10\*3 c/uL BASOPHILS (ABSOLUTE) x10\*9 c/L 8.3 BASOA IF VALUE \> 400/MM3 MONOCYTES (ABSOLUTE) x10\*9 c/L 8.3 MONOA IF VALUE \> 2000/MM3 LYMPHOCYTES (ABSOLUTE) x10\*9 c/L 8.3 LYMPA IF VALUE \< .750 X10\*3 c/uL OR IF VALUE \> 7.50 X10\*3 c/uL N = the number of participants with at least 1 on treatment lab result for each analyte
Time frame: Day 1 to Day 729
Number of Participants With Marked Liver and Kidney Function Laboratory Abnormalities in the Double Blind Period
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value ALKALINE PHOSPHATASE (ALP) U/L 5.0 ALP \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX ASPARTATE AMINOTRANSFERASE (AST) U/L 5.0 AST \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX ALANINE AMINOTRANSFERASE (ALT) U/L 5.0 ALT \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX G-GLUTAMYL TRANSFERASE (GGT) U/L 5.0 GGT \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX BILIRUBIN, TOTAL umol/L 5.1 TBILI \>2X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX BILIRUBIN, DIRECT umol/L 5.1 DBILI \>1.5X ULN, OR IF PRE RX\>ULN THEN USE \>2X PRE RX BLOOD UREA NITROGEN mmol/L 5.1 BUN \>2X PRE RX CREATININE umol/L 5.0 CREAT \>1.5X PRE RX N = the number of participants with at least 1 on treatment lab result for each analyte
Time frame: Day 1 to Day 729
Number of Participants With Marked Electrolyte Laboratory Abnormalities in the Double Blind Period
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value SODIUM, SERUM mmol/L 4.0 NA \<0.95X LLN OR \>1.05X ULN, OR IF PRE RX\<LLN THEN USE \<0.95X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.05X PRE RX OR \<LLN POTASSIUM, SERUM mmol/L 4.1 K \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN CHLORIDE, SERUM mmol/L 5.0 CL \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN N = the number of participants with at least 1 on treatment lab result for each analyte
Time frame: Day 1 to Day 729
Number of Participants With Marked Urinalysis Laboratory Abnormalities in the Double Blind Period
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value PROTEIN, URINE Unknown UPRO IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 GLUCOSE, URINE N/A UGLU IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 BLOOD, URINE N/A UBLD IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 RBC, URINE hpf 5.0 URBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 WBC, URINE hpf 5.0 UWBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4
Time frame: Day 1 to Day 729
Number of Participants With Other Marked Chemistry Laboratory Abnormalities in the Double Blind Period
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value CALCIUM, TOTAL mmol/L 5.2 CA \<0.8X LLN OR \>1.2X ULN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.25X PRE RX OR \<LLN PHOSPHORUS, INORGANIC mmol/L 5.2 PHOS \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.67X PRE RX OR \>ULN GLUCOSE, SERUM mmol/L 4.1 GLUC \<65 mg/dL, OR \>220 mg/dL PROTEIN, TOTAL g/L 5.0 TPRO \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE 0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE 1.1X PRE RX OR \<LLN ALBUMIN g/L 3.0 ALB \<0.9X LLN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX CHOLESTEROL, TOTAL (TC) mmol/L 5.2 CHOL \>2X PRE R N = the number of participants with at least 1 on treatment lab result for each analyte
Time frame: Day 1 to Day 729
Number of Participants With Abatacept Induced Antibody Response Over Time in the Double-blind Period
Participants who experienced a positive antibody response relative to baseline (ECL Assay)
Time frame: Day 365, Day 729
| Milestone | Abatacept IV | Placebo IV |
|---|---|---|
| Started | 203 | 203 |
| Treated | 202 | 203 |
| Completed | 155 | 161 |
| Not completed | 48 | 42 |
| Withdrew: Lack of efficacy | 11 | 9 |
| Withdrew: Adverse event | 20 | 17 |
| Withdrew: Withdrawal by subject | 6 | 7 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Poor / non-compliance | 0 | 1 |
| Withdrew: Pregnancy | 2 | 0 |
| Withdrew: Participant no longer meets criteria | 6 | 2 |
| Withdrew: Not treated- received ace inhibition | 1 | 0 |
| Withdrew: Change in concomitant medication | 0 | 1 |
| Withdrew: Need of use of prohibited medications | 1 | 0 |
| Withdrew: Antiproteinuric changed/dose increased | 0 | 1 |
| Withdrew: Hypersensitivity to the medication | 0 | 1 |
| Milestone | Abatacept IV | Placebo IV |
|---|---|---|
| Started | 155 | 161 |
| Completed | 129 | 123 |
| Not completed | 26 | 38 |
| Withdrew: Lack of efficacy | 4 | 12 |
| Withdrew: Adverse event | 7 | 6 |
| Withdrew: Participant request to stop treatment | 4 | 4 |
| Withdrew: Administrative reason by sponsor | 4 | 3 |
| Withdrew: Participant withdrew consent | 1 | 5 |
| Withdrew: Participant no longer meets criteria | 1 | 4 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Participant went to us stopped treatment | 0 | 1 |
| Withdrew: Pregnancy | 1 | 1 |
| Withdrew: Completed year 1, did not enter year 2 | 2 | 1 |
| Withdrew: Given cyclophosphamide, corticosteroids | 0 | 1 |
| Milestone | Abatacept IV | Placebo IV |
|---|---|---|
| Started | 129 | 123 |
| Completed | 62 | 53 |
| Not completed | 67 | 70 |
| Withdrew: Administrative reason by sponsor | 27 | 21 |
| Withdrew: Disease progression | 1 | 4 |
| Withdrew: Not effective | 0 | 1 |
| Withdrew: Participant request to stop treatment | 1 | 1 |
| Withdrew: Participant withdrew consent | 1 | 1 |
| Withdrew: Adverse event unrelated to study drug | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Study drug toxicity | 1 | 0 |
| Withdrew: Participant no longer meets criteria | 1 | 0 |
| Withdrew: Completed year 2, did not enter lte | 33 | 38 |
| Withdrew: Absence of renal response | 0 | 1 |
| Withdrew: Investigator decision, study termination | 0 | 1 |
| Withdrew: Study was terminated | 0 | 1 |
Number of participants achieving CR was divided by the total number of participants in that arm and expressed as a percentage. CR defined as: eGFR is normal or no \<85% of the baseline; eGFR based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equiv. for at least 28 days prior to assessment. Participants with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as having achieved CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use (Yes/No), race (Asian/ Black/Caucasian/Other) and baseline UPCR as a continuous variable.
| Percentage | Abatacept IV | Placebo IV |
|---|---|---|
| Percentage of Participants in Complete Renal Response (CR) of Lupus Glomerulonephritis at Day 365 of the Double-blind Period | 35.1 (0.8967 to 1.5726) | 33.5 |
Number of participants achieving CR was divided by total participants in that arm, expressed as a percentage. CR is defined the following criteria: eGFR is normal or no \<85% of the baseline value; eGFR is based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equivalent for at least 28 days prior. Subjects with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use, race and baseline UPCR as a continuous variable.
| Percentage | Abatacept IV | Placebo IV |
|---|---|---|
| Percentage of Nephrotic Participants in Complete Renal Response of Lupus Glomerulonephritis at Day 365 of the Double-blind Period | 27 (0.8967 to 1.5726) | 29.5 |
Adjusted Mean Change from Baseline in UPCR at Day 365 of the double-blind period in nephrotic participants
| UPCR (mg/mg) | Abatacept IV | Placebo IV |
|---|---|---|
| Adjusted Mean Change From Baseline in Urine Protein/Creatinine Ratio (UPCR) at Day 365 of the Double-blind Period in Nephrotic Participants | -5.01 ± 0.33 | -4.84 ± 0.35 |
Adjusted Mean Change from Baseline in Urine protein/creatinine ratio (UPCR) at Day 365 of the double-blind period in the overall population
| UPCR (mg/mg) | Abatacept IV | Placebo IV |
|---|---|---|
| Adjusted Mean Change From Baseline in UPCR at Day 365 of the Double-blind Period in Overall Population | -2.99 ± 0.17 | -2.90 ± 0.16 |
Adjusted mean change from baseline in British Isles Lupus Assessment Group (BILAG) score over time during Year 1 of the double-blind period based on a repeated measure mixed model and presented at each visit in the first 12-month of the double-blind period. BILAG index measures disease activity in different organs/systems separately. BILAG score is calculated for each of 9 systems depending on the clinical features present and whether they are new (4 points), worse (3 points), the same (2 points), improving (1 point) or not present (0 points) in the last 4 weeks compared with previously. BILAG "A" represents the presence of serious features of lupus. BILAG "B" represents more moderate features of the disease. BILAG "C" includes only mild symptomatic features. BILAG "D" represents prior activity with no current symptoms due to active lupus. BILAG "E" represents an organ that has never been involved. Overall BILAG score ranges from 0-108, with higher scores reflecting a worse outcome.
| Scores on a Scale | Abatacept IV | Placebo IV |
|---|---|---|
| Adjusted Mean Change From Baseline in Disease Activity as Measured by BILAG 2004 Over Time During Year 1 of the Double-blind Period | -8.22 (-9.29 to -7.16) | -7.60 (-8.66 to -6.54) |
All AEs were coded and grouped into preferred terms (PT) by system organ class (SOC), using the Medical Dictionary for Regulatory Activities (MedDRA, version 21.0). Investigators determined the intensity of each AE as mild, moderate, severe, or very severe and assessed the relationship to study drug.
| Participants | Abatacept IV | Placebo IV |
|---|---|---|
| Participants with Adverse Events | 188 | 194 |
| Participants with Serious Adverse Events | 49 | 39 |
| Participants with infection Adverse Events | 150 | 147 |
| Participants with malignancies | 2 | 1 |
| Participants with autoimmune events | 10 | 9 |
| Participants with peri-infusional Adverse Events | 7 | 9 |
| Participants with acute infusional Adverse Events | 2 | 4 |
Complete Renal Response or Complete Response (CR): defined as meeting ALL of the following criteria: eGFR normal OR no less than 85% of the baseline value; UPCR \< 0.5; Urine sediment: No cellular casts; Daily corticosteroid dose must be no greater than 10 mg prednisone or equivalent for at least 28 days prior to assessment. Partial Renal Response or Partial Response (PR): defined as meeting ALL of the following criteria: Participant does not meet criteria for CR; eGFR no less than 85% of the lesser of the values at screening or randomization (Day 1); UPCR \< 0.5 OR 50% reduced from baseline and \< 1 if baseline value was \< 3, OR 50% reduced from baseline and \< 3 if baseline value was greater than or equal to 3; Urine sediment: no cellular casts; daily corticosteroid dose no greater than 10 mg/day prednisone or prednisone equivalent for at least 28 days prior to assessment. No Renal Response or No Response (NR): defined as not meeting criteria for CR or PR or withdrawn
| Percentage | Abatacept IV | Placebo IV |
|---|---|---|
| CR - Day 365 | 35.1 | 33.5 |
| PR - Day 365 | 20.8 | 21.7 |
| NR - Day 365 | 44.1 | 44.8 |
| CR - Day 729 | 60.7 | 53.6 |
| PR - Day 729 | 25.9 | 22.7 |
| NR - Day 729 | 13.4 | 23.6 |
The estimate of median time to Complete Renal Response is based on Kaplan-Meier analysis. Complete renal response (CR): defined as meeting ALL of the following criteria: eGFR normal OR no less than 85% of the baseline value; Urine protein/creatinine ratio (UPCR) \< 0.5; Urine sediment: No cellular casts; Daily corticosteroid dose must be no greater than 10 mg prednisone or equivalent for at least 28 days prior to assessment.
| Days | Abatacept IV | Placebo IV |
|---|---|---|
| Day 365 | 280.0 (198.0 to 365.0) | 309.0 (280.0 to 365.0) |
| Day 729 | 170.0 (141.0 to 225.0) | 282.0 (225.0 to 357.0) |
The estimate of median time to Complete Renal Response in nephrotic participants is based on Kaplan-Meier analysis. Complete renal response (CR): defined as meeting ALL of the following criteria: eGFR normal OR no less than 85% of the baseline value; Urine protein/creatinine ratio (UPCR) \< 0.5; Urine sediment: No cellular casts; Daily corticosteroid dose must be no greater than 10 mg prednisone or equivalent for at least 28 days prior to assessment.
| Days | Abatacept IV | Placebo IV |
|---|---|---|
| Day 365 | 366.0 (337.0 to NA) | 368.0 (311.0 to 368.0) |
| Day 729 | 365.0 (197.0 to 644.0) | 368.0 (308.0 to 505.0) |
The estimate of median time to Partial Response (PR) is based on Kaplan-Meier analysis. Partial renal response (PR): defined as meeting ALL of the following criteria: Participant does not meet criteria for CR; eGFR no less than 85% of the lesser of the values at screening or randomization (Day 1); UPCR \< 0.5 OR 50% reduced from baseline and \< 1 if baseline value was \< 3, OR 50% reduced from baseline and \< 3 if baseline value was 3; Urine sediment: no cellular casts; daily corticosteroid dose no greater than 10 mg/day prednisone or prednisone equivalent for at least 28 days prior to assessment
| Days | Abatacept IV | Placebo IV |
|---|---|---|
| Day 365 | 226.0 (198.0 to 313.0) | 253.0 (198.0 to 358.0) |
| Day 729 | 59.0 (56.0 to 85.0) | 58.0 (57.0 to 85.0) |
The estimate of median time to Partial Response (PR) in nephrotic participants is based on Kaplan-Meier analysis. Partial renal response (PR): defined as meeting ALL of the following criteria: Participant does not meet criteria for CR; eGFR no less than 85% of the lesser of the values at screening or randomization (Day 1); UPCR \< 0.5 OR 50% reduced from baseline and \< 1 if baseline value was \< 3, OR 50% reduced from baseline and \< 3 if baseline value was 3; Urine sediment: no cellular casts; daily corticosteroid dose no greater than 10 mg/day prednisone or prednisone equivalent for at least 28 days prior to assessment
| Days | Abatacept IV | Placebo IV |
|---|---|---|
| Day 365 | 225.0 (196.0 to 311.0) | 196.0 (170.0 to 225.0) |
| Day 729 | 58.5 (29.0 to 86.0) | 56.0 (29.0 to 58.0) |
A repeated measure mixed model that included the baseline UPCR value, randomization stratification factors, time, and time by treatment interaction as fixed effects and subject as a random effect was used.
| UPCR (mg/mg) | Abatacept IV | Placebo IV |
|---|---|---|
| Day 365 | -2.95 ± 0.17 | -2.68 ± 0.17 |
| Day 729 | -3.13 ± 0.18 | -2.72 ± 0.18 |
A repeated measure mixed model that included the baseline UPCR value, randomization stratification factors, time, and time by treatment interaction as fixed effects and subject as a random effect was used. % Change from Baseline = (post baseline - baseline value) / baseline value x 100
| Percent | Abatacept IV | Placebo IV |
|---|---|---|
| Day 365 | -83.77 (-92.42 to -64.18) | -84.12 (-94.03 to -59.98) |
| Day 729 | -89.83 (-95.41 to -77.95) | -87.28 (-93.78 to -66.43) |
Estimated glomerular filtration rate(eGFR), will be calculated by the CKD-EPI formula shown below.50 eGFR is expressed as mL/min per 1.73m2. For the purpose of this study lower limit of normal eGFR is defined as 90mL/min per 1.73m2 eGFR = 141 X min (Scr/k, 1)α X max (Scr/k, 1)-1.209 X 0.993Age X (1.018 \[if female\]) X (1.159 \[if black\]) Where Scr is serum creatinine (mg/dL), k is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/k or 1, and max indicates the maximum of Scr/k or 1, age in years.
| mL/min per 1.73m2 | Abatacept IV | Placebo IV |
|---|---|---|
| Day 365 | 6.85 (3.47 to 10.23) | 5.85 (2.51 to 9.20) |
| Day 729 | 7.20 (3.40 to 11.00) | 7.91 (4.14 to 11.68) |
Sustained response defined as response present at 2 consecutive visits approximately 4 weeks apart. No renal response (NR): defined as not meeting criteria for CR or PR or withdrawn The estimate of median time is based on Kaplan-Meier analysis
| Days | Abatacept IV | Placebo IV |
|---|---|---|
| Day 365 | NA (392.0 to NA) | NA (NA to NA) |
| Day 729 | NA (NA to NA) | NA (672.0 to NA) |
Sustained change to no response is defined as going from CR (or PR) to NR and remaining in NR for at least 2 consecutive visits; visits should be approximately 4 weeks apart. This analysis will be based on time from response CR (or PR) to the first visit in which the no response (NR) was achieved and sustained to the next visit.
| Participants | Abatacept IV | Placebo IV |
|---|---|---|
| Day 365 | 5 | 3 |
| Day 729 | 52 | 56 |
BILAG index measures and reports disease activity in different organs/systems separately. The BILAG score is calculated for each of nine systems depending on the clinical features present and whether they are new (4 points), worse (3 points), the same (2 points), improving (1 point) or not present (0 points) in the last 4 weeks compared with previously. A BILAG "A" represents the presence of one or more serious features of lupus. A BILAG "B" represents more moderate features of the disease. A BILAG "C" includes only mild symptomatic features. A BILAG "D" represents only prior activity with no current symptoms due to active lupus. A BILAG "E" represents an organ that has never been involved. Overall BILAG score ranges from 0-108, with higher scores reflecting a worse outcome.
| Scores on a Scale | Abatacept IV | Placebo IV |
|---|---|---|
| Day 1 to Day 729 | -9.31 ± 0.56 | -8.53 ± 0.56 |
| Day 365 to Day 729 | -0.95 ± 0.538 | -0.40 ± 0.530 |
Trough level serum concentration of abatacept prior to the administration of the IV infusion on Days 1 to 365
| ug/mL | Abatacept IV | Placebo IV |
|---|---|---|
| Day 15 | 69.97 ± 91.4 | — |
| Day 29 | 90.46 ± 56.8 | — |
| Day 57 | 36.43 ± 84.4 | — |
| Day 85 | 34.46 ± 55.4 | — |
| Day 113 | 16.42 ± 69.2 | — |
| Day 169 | 13.98 ± 64.5 | — |
| Day 281 | 14.44 ± 54.7 | — |
| Day 337 | 14.99 ± 73.6 | — |
| Day 365 | 13.62 ± 51.7 | — |
Cmax: Maximum observed serum concentration following participants receiving active abatacept IV
| ug/mL | Abatacept IV | Placebo IV |
|---|---|---|
| Day 1 | 527.43 ± 59.6 | — |
| Day 337 | 203.51 ± 30.6 | — |
AUC (TAU): Area under the serum concentration time curve over a dosing interval between Days 337 to 365.
| ug*h/mL | Abatacept IV | Placebo IV |
|---|---|---|
| AUC (TAU): Area Under the Serum Concentration Time Curve Over a Dosing Interval | 36480.24 ± 29.2 | — |
Summary statistics for systolic blood pressure
| mmHg | Abatacept IV | Placebo IV |
|---|---|---|
| Day 1, end of observation | 122.0 ± 15.48 | 122.6 ± 15.31 |
| Day 365, end of observation | 112.3 ± 18.45 | 115.0 ± 7.07 |
| Day 729, end of observation | 108.6 ± 13.29 | 114.2 ± 14.51 |
Summary statistics for diastolic blood pressure
| mmHg | Abatacept IV | Placebo IV |
|---|---|---|
| Day 1, end of observation | 76.5 ± 11.49 | 77.0 ± 11.19 |
| Day 365, end of observation | 73.5 ± 10.75 | 77.5 ± 10.61 |
| Day 729, end of observation | 67.5 ± 9.60 | 72.7 ± 9.45 |
Summary statistics for Heart Rate
| beats per minute | Abatacept IV | Placebo IV |
|---|---|---|
| Day 1, end of observation | 80.6 ± 10.91 | 81.4 ± 10.64 |
| Day 365, end of observation | 78.5 ± 9.57 | 70.0 ± 14.14 |
| Day 729, end of observation | 76.2 ± 11.69 | 76.7 ± 10.36 |
Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.
| U/L | Abatacept IV | Placebo IV |
|---|---|---|
| ALANINE AMINOTRANSFERASE (ALT) (U/L) | -2.2 (-4.834 to 0.382) | -3.4 (-6.462 to -0.435) |
| ALKALINE PHOSPHATASE (ALP) (U/L) | 8.2 (4.514 to 11.967) | 11.7 (7.125 to 16.202) |
| ASPARTATE AMINOTRANSFERASE (AST) (U/L) | 0.3 (-1.747 to 2.288) | 0.3 (-1.326 to 1.947) |
| G-GLUTAMYL TRANSFERASE (GGT) (U/L) | -5.3 (-11.020 to 0.509) | -4.1 (-11.419 to 3.143) |
Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.
| g/L | Abatacept IV | Placebo IV |
|---|---|---|
| ALBUMIN (g/L) | 9.2 (8.040 to 10.336) | 8.1 (6.917 to 9.308) |
| HEMOGLOBIN (g/L) | 8.8 (5.977 to 11.574) | 9.0 (5.480 to 12.449) |
| PROTEIN, TOTAL (g/L) | 9.9 (8.135 to 11.579) | 10.1 (8.438 to 11.786) |
Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.
| Percentage | Abatacept IV | Placebo IV |
|---|---|---|
| Mean Change From Baseline in Laboratory Analytes During the Double-blind Period (Percentage of Blood) | 0.0328 (0.023873 to 0.041658) | 0.0325 (0.021813 to 0.043160) |
Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.
| umol/L | Abatacept IV | Placebo IV |
|---|---|---|
| BILIRUBIN, TOTAL (umol/L) | 1.77 (1.0751 to 2.4633) | 1.00 (0.5112 to 1.4922) |
| CREATININE (umol/L) | -5.6 (-9.306 to -1.912) | -6.2 (-10.764 to -1.598) |
Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.
| mmol/L | Abatacept IV | Placebo IV |
|---|---|---|
| BLOOD UREA NITROGEN (mmol/L) | -2.31 (-2.9879 to -1.6241) | -2.25 (-2.8370 to -1.6682) |
| CALCIUM, TOTAL (mmol/L) | 0.097 (0.06893 to 0.12566) | 0.108 (0.07754 to 0.13850) |
| CHLORIDE, SERUM (mmol/L) | -1.1 (-1.675 to -0.461) | -0.5 (-1.244 to 0.192) |
| GLUCOSE, SERUM (mmol/L) | -0.23 (-0.4924 to 0.0424) | -0.58 (-0.9623 to -0.1902) |
| PHOSPHORUS, INORGANIC (mmol/L) | -0.077 (-0.12699 to -0.02654) | -0.037 (-0.08152 to 0.00807) |
| POTASSIUM, SERUM (mmol/L) | -0.02 (-0.0947 to 0.0646) | -0.10 (-0.2115 to 0.0029) |
| SODIUM, SERUM (mmol/L) | -0.2 (-0.762 to 0.280) | -0.5 (-1.060 to 0.078) |
Laboratory assessments were analyzed centrally, with the exception of pregnancy testing. Blood draws and urine collections were performed at visits specified in the protocol. Change from Baseline = Post-baseline - Baseline value.
| x10^9 cells/L | Abatacept IV | Placebo IV |
|---|---|---|
| EOSINOPHILS (ABSOLUTE) (x10^9 cells/L) | 0.034 (0.01182 to 0.05611) | 0.010 (-0.01781 to 0.03781) |
| LYMPHOCYTES (ABSOLUTE) (x10^9 cells/L) | 0.141 (-0.01315 to 0.29584) | -0.149 (-0.29961 to 0.00138) |
| MONOCYTES (ABSOLUTE) (x10^9 cells/L) | -0.018 (-0.05220 to 0.01649) | -0.050 (-0.09264 to -0.00772) |
| NEUTROPHILS (ABSOLUTE) (x10^9 cells/L) | -2.259 (-2.78568 to -1.73210) | -2.289 (-2.95652 to -1.62118) |
| PLATELET COUNT (x10^9 cells/L) | -4.9 (-16.962 to 7.148) | -9.1 (-24.094 to 5.951) |
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value HEMOGLOBIN g/L 4.0 HB \>3 G/DL DECREASE FROM PRE RX HEMATOCRIT vol 6.3 HCT \<0.75X PRE RX ERYTHROCYTES x10\*12 c/L 5.2 RBC \<0.75X PRE RX PLATELET COUNT x10\*9 c/L 5.0 PLAT \<0.67X LLN OR \>1.5X ULN, OR IF PRE RX\<LLN THEN USE 0.5X PRE RX AND \<100,000/MM3 LEUKOCYTES x10\*9 c/L 6.2 WBC \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.8X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.2X PRE RX OR \<LLN EOSINOPHILS (ABSOLUTE) x10\*9 c/L 8.3 EOSA IF VALUE \> .750 X10\*3 c/uL BASOPHILS (ABSOLUTE) x10\*9 c/L 8.3 BASOA IF VALUE \> 400/MM3 MONOCYTES (ABSOLUTE) x10\*9 c/L 8.3 MONOA IF VALUE \> 2000/MM3 LYMPHOCYTES (ABSOLUTE) x10\*9 c/L 8.3 LYMPA IF VALUE \< .750 X10\*3 c/uL OR IF VALUE \> 7.50 X10\*3 c/uL N = the number of participants with at least 1 on treatment lab result for each analyte
| participants | Abatacept IV | Placebo IV |
|---|---|---|
| HEMOGLOBIN, low | 6 | 10 |
| HEMOGLOBIN, high | NA | NA |
| HEMATOCRIT, low | 12 | 12 |
| HEMATOCRIT, high | NA | NA |
| ERYTHROCYTES, low | 7 | 10 |
| ERYTHROCYTES, high | NA | NA |
| PLATELET COUNT, low | 4 | 3 |
| PLATELET COUNT, high | 0 | 0 |
| LEUKOCYTES, low | 35 | 21 |
| LEUKOCYTES, high | 29 | 25 |
| EOSINOPHILS (ABSOLUTE), low | NA | NA |
| EOSINOPHILS (ABSOLUTE), high | 2 | 6 |
| BASOPHILS (ABSOLUTE), low | NA | NA |
| BASOPHILS (ABSOLUTE), high | 1 | 1 |
| MONOCYTES (ABSOLUTE), low | NA | NA |
| MONOCYTES (ABSOLUTE), high | 0 | 1 |
| LYMPHOCYTES (ABSOLUTE), low | 81 | 104 |
| LYMPHOCYTES (ABSOLUTE), high | 1 | 2 |
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value ALKALINE PHOSPHATASE (ALP) U/L 5.0 ALP \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX ASPARTATE AMINOTRANSFERASE (AST) U/L 5.0 AST \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX ALANINE AMINOTRANSFERASE (ALT) U/L 5.0 ALT \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX G-GLUTAMYL TRANSFERASE (GGT) U/L 5.0 GGT \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX BILIRUBIN, TOTAL umol/L 5.1 TBILI \>2X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX BILIRUBIN, DIRECT umol/L 5.1 DBILI \>1.5X ULN, OR IF PRE RX\>ULN THEN USE \>2X PRE RX BLOOD UREA NITROGEN mmol/L 5.1 BUN \>2X PRE RX CREATININE umol/L 5.0 CREAT \>1.5X PRE RX N = the number of participants with at least 1 on treatment lab result for each analyte
| participants | Abatacept IV | Placebo IV |
|---|---|---|
| ALKALINE PHOSPHATASE (ALP), low | NA | NA |
| ALKALINE PHOSPHATASE (ALP), high | 1 | 1 |
| ASPARTATE AMINOTRANSFERASE (AST), low | NA | NA |
| ASPARTATE AMINOTRANSFERASE (AST), high | 5 | 0 |
| ALANINE AMINOTRANSFERASE (ALT), low | NA | NA |
| ALANINE AMINOTRANSFERASE (ALT), high | 8 | 2 |
| G-GLUTAMYL TRANSFERASE (GGT), low | NA | NA |
| G-GLUTAMYL TRANSFERASE (GGT), high | 17 | 15 |
| BILIRUBIN, TOTAL, low | NA | NA |
| BILIRUBIN, TOTAL, high | 0 | 0 |
| BILIRUBIN, DIRECT, low | NA | NA |
| BILIRUBIN, DIRECT, high | 0 | 0 |
| BLOOD UREA NITROGEN, low | NA | NA |
| BLOOD UREA NITROGEN, high | 20 | 12 |
| CREATININE, low | NA | NA |
| CREATININE, high | 24 | 20 |
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value SODIUM, SERUM mmol/L 4.0 NA \<0.95X LLN OR \>1.05X ULN, OR IF PRE RX\<LLN THEN USE \<0.95X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.05X PRE RX OR \<LLN POTASSIUM, SERUM mmol/L 4.1 K \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN CHLORIDE, SERUM mmol/L 5.0 CL \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN N = the number of participants with at least 1 on treatment lab result for each analyte
| participants | Abatacept IV | Placebo IV |
|---|---|---|
| SODIUM, SERUM, low | 1 | 1 |
| SODIUM, SERUM, high | 2 | 2 |
| POTASSIUM, SERUM, low | 3 | 5 |
| POTASSIUM, SERUM, high | 7 | 7 |
| CHLORIDE, SERUM, low | 0 | 1 |
| CHLORIDE, SERUM, high | 0 | 0 |
| CALCIUM, TOTAL, low | 1 | 1 |
| CALCIUM, TOTAL, high | 2 | 0 |
| PHOSPHORUS, INORGANIC, low | 9 | 7 |
| PHOSPHORUS, INORGANIC, high | 13 | 13 |
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value PROTEIN, URINE Unknown UPRO IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 GLUCOSE, URINE N/A UGLU IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 BLOOD, URINE N/A UBLD IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 RBC, URINE hpf 5.0 URBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 WBC, URINE hpf 5.0 UWBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4
| participants | Abatacept IV | Placebo IV |
|---|---|---|
| PROTEIN, URINE, low | NA | NA |
| PROTEIN, URINE, high | 0 | 0 |
| GLUCOSE, URINE, low | NA | NA |
| GLUCOSE, URINE, high | 0 | 0 |
| BLOOD, URINE, low | NA | NA |
| BLOOD, URINE, high | 0 | 0 |
| Red blood cells (RBC), URINE, low | NA | NA |
| Red blood cells (RBC), URINE, high | 93 | 103 |
| White blood cells (WBC), URINE, low | NA | NA |
| White blood cells (WBC), URINE, high | 91 | 98 |
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value CALCIUM, TOTAL mmol/L 5.2 CA \<0.8X LLN OR \>1.2X ULN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.25X PRE RX OR \<LLN PHOSPHORUS, INORGANIC mmol/L 5.2 PHOS \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.67X PRE RX OR \>ULN GLUCOSE, SERUM mmol/L 4.1 GLUC \<65 mg/dL, OR \>220 mg/dL PROTEIN, TOTAL g/L 5.0 TPRO \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE 0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE 1.1X PRE RX OR \<LLN ALBUMIN g/L 3.0 ALB \<0.9X LLN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX CHOLESTEROL, TOTAL (TC) mmol/L 5.2 CHOL \>2X PRE R N = the number of participants with at least 1 on treatment lab result for each analyte
| participants | Abatacept IV | Placebo IV |
|---|---|---|
| GLUCOSE, SERUM, low | 33 | 29 |
| GLUCOSE, SERUM, high | 10 | 5 |
| PROTEIN, TOTAL, low | 44 | 26 |
| PROTEIN, TOTAL, high | 0 | 1 |
| ALBUMIN, low | 10 | 11 |
| ALBUMIN, high | NA | NA |
All AEs were coded and grouped into preferred terms (PT) by system organ class (SOC), using the Medical Dictionary for Regulatory Activities (MedDRA, version 21.0). Investigators determined the intensity of each AE as mild, moderate, severe, or very severe and assessed the relationship to study drug.
| Participants | Abatacept IV | Placebo IV |
|---|---|---|
| Participants with Adverse Events | 127 | 137 |
| Participants with Serious Adverse Events | 15 | 25 |
| Participants with infection Adverse Events | 100 | 107 |
| Participants with malignancies | 0 | 1 |
| Participants with autoimmune events | 7 | 11 |
Lupus treatment failure is defined as any of the following: Death, unless due to physical trauma or violence; Renal Flare; sustained doubling of creatinine from baseline (greater of Screening or Study Day 1 value); initiation of rescue therapy for treatment of active lupus nephritis after Study Week 20. Overall treatment failure is defined as lupus treatment failure plus discontinuation of study drug for any reason except death due to physical trauma or violence, pregnancy or administrative decision by Sponsor.
| Percentage | Abatacept IV | Placebo IV |
|---|---|---|
| Lupus treatment failure (LTF) - Day 365 | 3.5 (0.943 to 5.988) | 4.4 (1.602 to 7.265) |
| Overall treatment failure (OTF) - Day 365 | 4.5 (1.610 to 7.301) | 4.9 (1.949 to 7.903) |
| LTF - Day 729 | 4.5 (1.0 to 8.0) | 5.3 (1.5 to 9.2) |
| OTF - Day 729 | 5.2 (1.5 to 9.0) | 8.4 (3.6 to 13.1) |
First treatment failure (or Lupus treatment failure) is defined as any of the following: Death, unless due to physical trauma or violence; Renal Flare; sustained doubling of creatinine from baseline (greater of Screening or Study Day 1 value); initiation of rescue therapy for treatment of active lupus nephritis after Study Week 20. Overall treatment failure is defined as lupus treatment failure plus discontinuation of study drug for any reason except death due to physical trauma or violence, pregnancy or administrative decision by Sponsor. The hazard ratio is estimated using the Cox proportional hazards model which includes treatment group, stratification variables (baseline ACEis/ARBs use, RACE) and baseline UPCR. The estimate of median time is based on Kaplan-Meier analysis
| Days | Abatacept IV | Placebo IV |
|---|---|---|
| First treatment failure (FTF) - Day 365 | NA (NA to NA) | NA (NA to NA) |
| Overall treatment failure (OTF) - Day 365 | NA (NA to NA) | NA (NA to NA) |
| FTF - Day 729 | NA (NA to NA) | NA (NA to NA) |
| OTF - Day 729 | NA (NA to NA) | NA (NA to NA) |
Number of participants achieving CR was divided by total participants in that arm, expressed as a percentage. CR is defined the following criteria: eGFR is normal or no \<85% of the baseline value; eGFR is based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equivalent for at least 28 days prior. Subjects with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use, race and baseline UPCR as a continuous variable.
| Percentage | Abatacept IV | Placebo IV |
|---|---|---|
| Percentage of Nephrotic Participants in Complete Renal Response of Lupus Glomerulonephritis at Day 729 of the Double-blind Period | 50.0 | 49.0 |
Number of participants achieving CR was divided by total participants in that arm, expressed as a percentage. CR is defined the following criteria: eGFR is normal or no \<85% of the baseline value; eGFR is based on mean creatinine value from day 358 and 365. Proteinuria: UPCR\<0.5 mg/mg. Urine sediment: No cellular casts. Corticosteroid dose: Daily dose must be no \>10 mg prednisone or equivalent for at least 28 days prior. Subjects with \>10mg/day prednisone or equivalent for non-renal disease within 28 days prior to day 365 will be imputed as CR if the following are true: Met all criteria for CR at day 337 and all criteria for CR except corticosteroid dose at day 365; Investigator confirms increase in steroid dose is not related to renal disease. Adjusted odds ratio is estimated from logistic regression model which includes treatment group, baseline ACEi/ARBs use, race and baseline UPCR as a continuous variable.
| Percentage | Abatacept IV | Placebo IV |
|---|---|---|
| Percentage of Participants in Overall Population in Complete Renal Response of Lupus Glomerulonephritis at Day 729 of the Double-blind Period | 61.9 | 52.7 |
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value HEMOGLOBIN g/L 4.0 HB \>3 G/DL DECREASE FROM PRE RX HEMATOCRIT vol 6.3 HCT \<0.75X PRE RX ERYTHROCYTES x10\*12 c/L 5.2 RBC \<0.75X PRE RX PLATELET COUNT x10\*9 c/L 5.0 PLAT \<0.67X LLN OR \>1.5X ULN, OR IF PRE RX\<LLN THEN USE 0.5X PRE RX AND \<100,000/MM3 LEUKOCYTES x10\*9 c/L 6.2 WBC \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.8X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.2X PRE RX OR \<LLN EOSINOPHILS (ABSOLUTE) x10\*9 c/L 8.3 EOSA IF VALUE \> .750 X10\*3 c/uL BASOPHILS (ABSOLUTE) x10\*9 c/L 8.3 BASOA IF VALUE \> 400/MM3 MONOCYTES (ABSOLUTE) x10\*9 c/L 8.3 MONOA IF VALUE \> 2000/MM3 LYMPHOCYTES (ABSOLUTE) x10\*9 c/L 8.3 LYMPA IF VALUE \< .750 X10\*3 c/uL OR IF VALUE \> 7.50 X10\*3 c/uL N = the number of participants with at least 1 on treatment lab result for each analyte
| participants | Abatacept IV | Placebo IV |
|---|---|---|
| HEMOGLOBIN, low | 8 | 9 |
| HEMOGLOBIN, high | NA | NA |
| HEMATOCRIT, low | 6 | 2 |
| HEMATOCRIT, high | NA | NA |
| ERYTHROCYTES, low | 4 | 2 |
| ERYTHROCYTES, high | NA | NA |
| PLATELET COUNT, low | 2 | 4 |
| PLATELET COUNT, high | 1 | 0 |
| LEUKOCYTES, low | 19 | 24 |
| LEUKOCYTES, high | 3 | 5 |
| EOSINOPHILS (ABSOLUTE), low | NA | NA |
| EOSINOPHILS (ABSOLUTE), high | 11 | 6 |
| BASOPHILS (ABSOLUTE), low | NA | NA |
| BASOPHILS (ABSOLUTE), high | 0 | 0 |
| MONOCYTES (ABSOLUTE), low | NA | NA |
| MONOCYTES (ABSOLUTE), high | 0 | 0 |
| LYMPHOCYTES (ABSOLUTE), low | 43 | 62 |
| LYMPHOCYTES (ABSOLUTE), high | 0 | 0 |
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value ALKALINE PHOSPHATASE (ALP) U/L 5.0 ALP \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX ASPARTATE AMINOTRANSFERASE (AST) U/L 5.0 AST \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX ALANINE AMINOTRANSFERASE (ALT) U/L 5.0 ALT \>3X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX G-GLUTAMYL TRANSFERASE (GGT) U/L 5.0 GGT \>2X ULN, OR IF PRE RX\>ULN THEN USE \>3X PRE RX BILIRUBIN, TOTAL umol/L 5.1 TBILI \>2X ULN, OR IF PRE RX\>ULN THEN USE \>4X PRE RX BILIRUBIN, DIRECT umol/L 5.1 DBILI \>1.5X ULN, OR IF PRE RX\>ULN THEN USE \>2X PRE RX BLOOD UREA NITROGEN mmol/L 5.1 BUN \>2X PRE RX CREATININE umol/L 5.0 CREAT \>1.5X PRE RX N = the number of participants with at least 1 on treatment lab result for each analyte
| participants | Abatacept IV | Placebo IV |
|---|---|---|
| ALKALINE PHOSPHATASE (ALP), low | NA | NA |
| ALKALINE PHOSPHATASE (ALP), high | 4 | 0 |
| ASPARTATE AMINOTRANSFERASE (AST), low | NA | NA |
| ASPARTATE AMINOTRANSFERASE (AST), high | 2 | 3 |
| ALANINE AMINOTRANSFERASE (ALT), low | NA | NA |
| ALANINE AMINOTRANSFERASE (ALT), high | 4 | 3 |
| G-GLUTAMYL TRANSFERASE (GGT), low | NA | NA |
| G-GLUTAMYL TRANSFERASE (GGT), high | 17 | 11 |
| BILIRUBIN, TOTAL, low | NA | NA |
| BILIRUBIN, TOTAL, high | 0 | 0 |
| BILIRUBIN, DIRECT, low | NA | NA |
| BILIRUBIN, DIRECT, high | 1 | 0 |
| BLOOD UREA NITROGEN, low | NA | NA |
| BLOOD UREA NITROGEN, high | 10 | 9 |
| CREATININE, low | NA | NA |
| CREATININE, high | 17 | 16 |
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value SODIUM, SERUM mmol/L 4.0 NA \<0.95X LLN OR \>1.05X ULN, OR IF PRE RX\<LLN THEN USE \<0.95X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.05X PRE RX OR \<LLN POTASSIUM, SERUM mmol/L 4.1 K \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN CHLORIDE, SERUM mmol/L 5.0 CL \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE \<0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.1X PRE RX OR \<LLN N = the number of participants with at least 1 on treatment lab result for each analyte
| participants | Abatacept IV | Placebo IV |
|---|---|---|
| SODIUM, SERUM, low | 0 | 0 |
| SODIUM, SERUM, high | 0 | 1 |
| POTASSIUM, SERUM, low | 2 | 2 |
| POTASSIUM, SERUM, high | 3 | 2 |
| CHLORIDE, SERUM, low | 0 | 1 |
| CHLORIDE, SERUM, high | 0 | 0 |
| CALCIUM, TOTAL, low | 0 | 0 |
| CALCIUM, TOTAL, high | 1 | 0 |
| PHOSPHORUS, INORGANIC, low | 3 | 4 |
| PHOSPHORUS, INORGANIC, high | 6 | 3 |
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value PROTEIN, URINE Unknown UPRO IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 GLUCOSE, URINE N/A UGLU IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 BLOOD, URINE N/A UBLD IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 RBC, URINE hpf 5.0 URBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4 WBC, URINE hpf 5.0 UWBC IF MISSING PRE THEN USE \>=2, OR IF VALUE \>=4, OR IF PRE RX =0 OR 0.5 THEN USE \>=2, OR IF PRE RX =1 THEN USE \>=3, OR IF PRE RX =2 OR 3 THEN USE \>=4
| participants | Abatacept IV | Placebo IV |
|---|---|---|
| PROTEIN, URINE, low | NA | NA |
| PROTEIN, URINE, high | 0 | 0 |
| GLUCOSE, URINE, low | NA | NA |
| GLUCOSE, URINE, high | 0 | 0 |
| BLOOD, URINE, low | NA | NA |
| BLOOD, URINE, high | 0 | 0 |
| Red blood cells (RBC), URINE, low | NA | NA |
| Red blood cells (RBC), URINE, high | 58 | 55 |
| White blood cells (WBC), URINE, low | NA | NA |
| White blood cells (WBC), URINE, high | 46 | 59 |
LLN= Lower limit of normals ULN= Upper limit of normals Pre RX = Baseline value CALCIUM, TOTAL mmol/L 5.2 CA \<0.8X LLN OR \>1.2X ULN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE \>1.25X PRE RX OR \<LLN PHOSPHORUS, INORGANIC mmol/L 5.2 PHOS \<0.75X LLN OR \>1.25X ULN, OR IF PRE RX\<LLN THEN USE \<0.67X PRE RX OR \>ULN GLUCOSE, SERUM mmol/L 4.1 GLUC \<65 mg/dL, OR \>220 mg/dL PROTEIN, TOTAL g/L 5.0 TPRO \<0.9X LLN OR \>1.1X ULN, OR IF PRE RX\<LLN THEN USE 0.9X PRE RX OR \>ULN, OR IF PRE RX\>ULN THEN USE 1.1X PRE RX OR \<LLN ALBUMIN g/L 3.0 ALB \<0.9X LLN, OR IF PRE RX\<LLN THEN USE \<0.75X PRE RX CHOLESTEROL, TOTAL (TC) mmol/L 5.2 CHOL \>2X PRE R N = the number of participants with at least 1 on treatment lab result for each analyte
| participants | Abatacept IV | Placebo IV |
|---|---|---|
| GLUCOSE, SERUM, low | 15 | 24 |
| GLUCOSE, SERUM, high | 3 | 2 |
| GLUCOSE, FASTING SERUM, low | 3 | 1 |
| GLUCOSE, FASTING SERUM, high | 3 | 1 |
| PROTEIN, TOTAL, low | 10 | 7 |
| PROTEIN, TOTAL, high | 2 | 3 |
| ALBUMIN, low | 4 | 5 |
| ALBUMIN, high | NA | NA |
Participants who experienced a positive antibody response relative to baseline (ECL Assay)
| Participants | Abatacept IV | Placebo IV |
|---|---|---|
| Day 365, overall | 7 | 9 |
Collected over From Day 1 up to 56 days post last dose (assessed up to May 2018, approximately 66 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept IV | 7/202 (3.5%) | 62/202 (30.7%) | 164/202 (81.2%) |
| Placebo IV | 6/203 (3%) | 58/203 (28.6%) | 179/203 (88.2%) |
| Event | Abatacept IV | Placebo IV |
|---|---|---|
| PneumoniaInfections and infestations | 15/202 | 6/203 |
| Herpes zosterInfections and infestations | 5/202 | 4/203 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 1/202 | 5/203 |
| Lupus nephritisRenal and urinary disorders | 4/202 | 2/203 |
| Urinary tract infectionInfections and infestations | 1/202 | 4/203 |
| AnaemiaBlood and lymphatic system disorders | 3/202 | 2/203 |
| PregnancyPregnancy, puerperium and perinatal conditions | 3/202 | 0/203 |
| EncephalitisInfections and infestations | 2/202 | 0/203 |
| GastroenteritisInfections and infestations | 2/202 | 2/203 |
| Genital herpesInfections and infestations | 2/202 | 0/203 |
| Event | Abatacept IV | Placebo IV |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 47/202 | 46/203 |
| Urinary tract infectionInfections and infestations | 45/202 | 38/203 |
| NasopharyngitisInfections and infestations | 40/202 | 44/203 |
| Upper respiratory tract infectionInfections and infestations | 43/202 | 42/203 |
| BronchitisInfections and infestations | 18/202 | 26/203 |
| CoughRespiratory, thoracic and mediastinal disorders | 25/202 | 24/203 |
| HeadacheNervous system disorders | 24/202 | 23/203 |
| PharyngitisInfections and infestations | 20/202 | 24/203 |
| AnaemiaBlood and lymphatic system disorders | 20/202 | 23/203 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 21/202 | 19/203 |
All Randomized and Treated Subjects
| Age, Continuous(years) | Abatacept IV | Placebo IV | Total |
|---|---|---|---|
| Mean | 33.1 ± 10.75 | 33.2 ± 10.48 | 33.1 ± 10.60 |
| Sex: Female, Male(Participants) | Abatacept IV | Placebo IV | Total |
|---|---|---|---|
| Female | 182 | 178 | 360 |
| Male | 20 | 25 | 45 |
| Race/Ethnicity, Customized(Participants) | Abatacept IV | Placebo IV | Total |
|---|---|---|---|
| Asian | 71 | 74 | 145 |
| African American | 15 | 15 | 30 |
| Caucasian | 85 | 71 | 156 |
| Other | 31 | 43 | 74 |
Showing the first 100 of 149 sites across 23 countries. Choose a country and city above to see the rest.
Ran from Jan 2013 to primary completion in Nov 2016, 45 months.
Results were first posted in Dec 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept